CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

Abstract Background In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a differential pattern of expression in a variety of tumors and cell lines...

Full description

Bibliographic Details
Main Authors: Juan Manuel Domínguez, Gema Pérez-Chacón, María José Guillén, María José Muñoz-Alonso, Beatriz Somovilla-Crespo, Danay Cibrián, Bárbara Acosta-Iborra, Magdalena Adrados, Cecilia Muñoz-Calleja, Carmen Cuevas, Francisco Sánchez-Madrid, Pablo Avilés, Juan M. Zapata
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Journal of Hematology & Oncology
Subjects:
CD13
ADC
Antibody-drug conjugate
MI130110
Fibrosarcoma
Endocytosis
Online Access:http://link.springer.com/article/10.1186/s13045-020-00865-7

Internet

http://link.springer.com/article/10.1186/s13045-020-00865-7

Similar Items